CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Implantable Hemodynamic Monitoring for Heart Failure Patients The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short Impact of Coronary Lesion Complexity in Percutaneous Coronary Intervention: One-Year Outcomes From the Large, Multicentre e-Ultimaster Registry Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond Myocardial Inflammation Predicts Remodeling and Neuroinflammation After Myocardial Infarction Association of Cardiovascular Disease With Respiratory Disease Switching P2Y12-receptor inhibitors in patients with coronary artery disease Rotational Atherectomy Followed by Drug-Coated Balloon Dilation for Left Main In-Stent Restenosis in the Setting of Acute Coronary Syndrome Complicated with Right Coronary Chronic Total Occlusion

Review Article2017 Jul 18;70(3):389-398.

JOURNAL:J Am Coll Cardiol. Article Link

Implantable Hemodynamic Monitoring for Heart Failure Patients

Abraham WT, Perl L. Keywords: disease management; hospitalization; patient readmission; pulmonary artery pressure; telemedicine

ABSTRACT


Rates of heart failure hospitalization remain unacceptably high. Such hospitalizations are associated with substantial patient, caregiver, and economic costs. Randomized controlled trials of noninvasive telemedical systems have failed to demonstrate reduced rates of hospitalization. The failure of these technologies may be due to the limitations of the signals measured. Intracardiac and pulmonary artery pressure-guided management has become a focus of hospitalization reduction in heart failure. Early studies using implantable hemodynamic monitors demonstrated the potential of pressure-based heart failure management, whereas subsequent studies confirmed the clinical utility of this approach. One large pivotal trial proved the safety and efficacy of pulmonary artery pressure-guided heart failure management, showing a marked reduction in heart failure hospitalizations in patients randomized to active pressure-guided management. "Next-generation" implantable hemodynamic monitors are in development, and novel approaches for the use of this data promise to expand the use of pressure-guided heart failure management.